Compare VITL & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VITL | ALLO |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 588.6M | 539.4M |
| IPO Year | 2020 | 2018 |
| Metric | VITL | ALLO |
|---|---|---|
| Price | $12.66 | $2.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 11 |
| Target Price | ★ $37.90 | $8.40 |
| AVG Volume (30 Days) | 2.6M | ★ 4.6M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.03 | ★ 34.09 |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $759,444,000.00 | N/A |
| Revenue This Year | $21.13 | N/A |
| Revenue Next Year | $18.17 | $140,929.80 |
| P/E Ratio | $8.74 | ★ N/A |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $12.35 | $0.86 |
| 52 Week High | $53.13 | $2.80 |
| Indicator | VITL | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 20.37 | 54.90 |
| Support Level | N/A | $2.14 |
| Resistance Level | $33.73 | $2.71 |
| Average True Range (ATR) | 0.90 | 0.23 |
| MACD | 0.19 | -0.00 |
| Stochastic Oscillator | 4.76 | 68.33 |
Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.